Gastrointestinal Neoplasms  >>  GEM 640  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GEM 640 / Pharmascience
NCT00557596 / 2007-005961-36: A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer

Terminated
1/2
48
US
AEG35156
Aegera Therapeutics
Carcinoma, Pancreas
11/09
11/09
NCT00882869: XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Checkmark AEG35156 in combination with sorafenib in pts with adv HCC
Jul 2014 - Jul 2014: AEG35156 in combination with sorafenib in pts with adv HCC
Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Completed
1/2
75
RoW
AEG35156 antisense IV infusion, Sorafenib, nexavar
Aegera Therapeutics, Chinese University of Hong Kong
Advanced Hepatocellular Carcinoma
03/11
05/11

Download Options